Clinical Trial Update: Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating NST-001 with the Neuroject Injection Set for tinnitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tinnitus

Drugs mentioned

• NST-001
• Neuroject Injection Set

Snippet

Sponsor: NeuroSystec Corporation | Conditions: Tinnitus | Phase 1 | Status: TERMINATED